BOZEN, Sud-Tirol, Italy, March 5, 2013 /PRNewswire/ --
Amerinet Choice®, the preferred portfolio subsidiary of Amerinet, announced a new five-year exclusive agreement with Health Robotics for its world-leading Sterile Compounding Automation solutions i.v.STATION, i.v.STATION ONCO, and i.v.SOFT Workflow Management solutions.
"We are very excited to offer to our members Health Robotics' revolutionary solutions for sterile compounding automation," said Gary Freeman, vice president of pharmacy for Amerinet. "IV patient safety and reduction of costs are of paramount importance to Amerinet and its members, especially in light of the recent trend in the healthcare industry to insource sterile compounding medications."
Sterile compounding safety has been at the forefront of the recent news coverage and increased regulatory oversight in the United States, especially in light of the deadly meningitis outbreak last year. Health Robotics' Robots are designed to prevent risks such as these, by compounding IV doses in an enclosed ISO-5 chamber, with multiple patient safety checks that can prevent human errors, the most common source of medication contamination and other medical mistakes.
Gaspar DeViedma, Health Robotics' executive vice president and board member, stated: "We are pleased indeed to have been exclusively selected by Amerinet Choice, for the provision of IV Robotics and IV Workflow solutions to their 3,100 member hospitals and more than 60,000 other healthcare providers."
As a leading national healthcare solutions organization, Amerinet collaborates with acute and non-acute care providers to create and deliver unique solutions through performance improvement resources, guidance and ongoing support. With better product standardization and utilization, new financial tools beyond contracting and alliances that help lower costs, raise revenue and champion quality, Amerinet enriches healthcare delivery for its members and the communities they serve. To learn more about how Amerinet can help you successfully navigate the future of healthcare reform, visit http://www.amerinet-gpo.com.
About Health Robotics:
Founded in 2006 and now reaching over 80% total IV Robots market share in the world [including over 90% of the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 350 hospital installations in 5 continents with the only fully-integrated robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies,] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput, and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
For additional information, please contact:
Director, Communications and Media
SOURCE Health Robotics